Does Affinity Health Plan Cover Jardiance? What Women Need to Know

What Affinity Health Plan Is and Why Formulary Details Are Complicated

Affinity Health Plan is a New York-based managed care organization that administers Medicaid Managed Care, Child Health Plus, and Essential Plan products, primarily for members in the New York City area. It does not offer standard commercial PPO or HMO plans in the way that large national insurers do. That distinction matters for Jardiance coverage because Medicaid formularies are set by each state Medicaid program and updated annually, and managed care organizations like Affinity operate under contracts with New York State Department of Health.

New York State Medicaid requires all managed care plans to cover a defined set of drugs, but preferred drug lists and tier placements vary by plan and by year. Affinity's formulary is published each January and is subject to mid-year changes.

How to Find Your Specific Affinity Formulary

The fastest way to confirm current Jardiance coverage is to:

1. Log into your Affinity member portal and search the drug lookup tool.
2. Call the Member Services number on the back of your insurance card and ask specifically whether NDC code 0597-0138-37 (Jardiance 10 mg, 30 tablets) is covered under your plan year.
3. Ask your prescribing clinician's office to run a real-time formulary check through their e-prescribing software before you leave the appointment.

Because Affinity serves a predominantly Medicaid population, your cost-sharing is often low or zero at point of sale even for Tier 3 drugs, provided prior authorization is approved. The hurdle is the authorization step, not the copay.

Prior Authorization: What Affinity Typically Requires

For Jardiance, prior authorization under most Medicaid-aligned plans requires documentation of:

• A confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.xx) or heart failure with reduced ejection fraction (HFrEF) or chronic kidney disease (CKD) stages 2-4.
• Trial and failure or contraindication to at least one preferred formulary agent (metformin for T2D; an ACE inhibitor or ARB for CKD).
• An HbA1c value, eGFR, or UACR result from within the past six months supporting clinical need.

Your clinician submits the prior authorization. You do not submit it yourself. Ask the prescribing office whether they use CoverMyMeds or a similar platform to track authorization status.

Why Jardiance Matters Differently for Women

Empagliflozin is an SGLT2 (sodium-glucose cotransporter-2) inhibitor. It lowers blood glucose by causing the kidneys to excrete excess glucose in urine. It also reduces blood pressure modestly, causes weight loss of roughly 2-3 kg, and has cardiovascular and kidney-protective effects that go beyond glucose lowering.

Those benefits are real for women, but women's biology changes how the drug works, what side effects show up, and how the risk-benefit calculation shifts across the lifespan.

Cardiovascular Risk in Women With Type 2 Diabetes

Women with type 2 diabetes lose the relative cardiovascular protection that pre-menopausal estrogen typically confers. After menopause, women with T2D have a risk of major adverse cardiovascular events (MACE) that is roughly equivalent to, or exceeds, the risk in men of the same age. The EMPA-REG OUTCOME trial, which enrolled 7,020 participants and showed a 14% relative risk reduction in MACE with empagliflozin versus placebo, included women in 29% of its population. The cardiovascular benefit held across sexes, though the trial was not statistically powered for sex-stratified subgroup analysis.

ADA Standards of Medical Care in Diabetes 2024 recommend an SGLT2 inhibitor with proven cardiovascular benefit as a preferred add-on agent in people with T2D and established cardiovascular disease or high cardiovascular risk, independent of HbA1c. This is the clinical language your prescriber can use in a prior authorization letter.

Kidney Protection and Women

Diabetic kidney disease progresses faster in women with poorly controlled T2D than historical data suggested, partly because women present later and with more advanced disease. The CREDENCE trial (canagliflozin, a related SGLT2 inhibitor) and the EMPA-KIDNEY trial demonstrated kidney-protective effects in patients with CKD and albuminuria. These data support SGLT2 inhibitor use in women with diabetic nephropathy who may qualify for coverage under the CKD indication even if their T2D is relatively well controlled.

Weight and Metabolic Effects Across the Menstrual Cycle and Menopause

Empagliflozin causes modest weight loss, typically 2-3 kg over 24 weeks, by increasing urinary caloric excretion. In post-menopausal women, where visceral adiposity increases and insulin sensitivity declines, this mechanism may be particularly useful. The weight loss is not large enough to replace GLP-1 receptor agonist therapy for women whose primary goal is significant weight reduction, but it adds meaningful metabolic benefit when chosen for cardiovascular or kidney indications.

During reproductive years, your menstrual cycle affects insulin sensitivity. Progesterone in the luteal phase (days 15-28) reduces insulin sensitivity, which can raise glucose even in women with well-controlled T2D. Empagliflozin's mechanism is glucose-dependent and does not cause hypoglycemia on its own, which makes it a reasonable choice for women who experience cycle-related glucose variability.

PCOS and Jardiance: What the Evidence Actually Shows

Polycystic ovary syndrome (PCOS) affects roughly 8-13% of women of reproductive age and is characterized by hyperandrogenism, ovulatory dysfunction, and insulin resistance. Insulin resistance is present in approximately 70% of women with PCOS regardless of BMI. Metformin is the insulin-sensitizing drug with the most evidence and is guideline-endorsed for PCOS-related metabolic concerns by the 2023 International Evidence-Based Guideline for PCOS.

SGLT2 inhibitors, including empagliflozin, are being studied in PCOS for their insulin-sensitizing and androgen-lowering potential, but as of 2025 there are no randomized controlled trials of sufficient size to support routine off-label prescribing. Small studies suggest reductions in fasting insulin and free androgen index, but this is not sufficient evidence for guideline endorsement.

Here is a practical framework for women with PCOS asking about Jardiance coverage:

• If you have PCOS plus type 2 diabetes: Jardiance is on-label and the cardiovascular/metabolic rationale supports coverage approval.
• If you have PCOS plus prediabetes and high cardiovascular risk: Off-label use may be clinically supported but prior authorization approval is unlikely without a T2D or CKD diagnosis code.
• If you have PCOS and normal glucose tolerance: Metformin remains the first-line insulin sensitizer with evidence and coverage.

Pregnancy, Lactation, and Contraception: Read This Before You Fill the Prescription

This section is mandatory reading for any woman of reproductive age taking or considering Jardiance.

Pregnancy

Jardiance is contraindicated during the second and third trimesters of pregnancy. Animal studies show kidney development abnormalities when SGLT2 inhibitors are given during the equivalent of the second and third trimesters. Human data are limited; the post-marketing pregnancy exposure registry (the Jardiance Pregnancy Exposure Registry, NCT02131311) has insufficient numbers for definitive conclusions.

The FDA prescribing information advises that Jardiance should be discontinued as soon as pregnancy is detected. If you are trying to conceive, discuss a transition plan with your clinician before you stop contraception. First-trimester data in humans are sparse, and the cautious clinical approach is to switch to a pregnancy-compatible agent before conception, not after a positive test.

ACOG's guidance on pregestational diabetes recommends insulin as the primary pharmacologic agent for glucose management in pregnancy, with metformin as an acceptable adjunct in some cases. No SGLT2 inhibitor is recommended during pregnancy.

Lactation

Empagliflozin transfer into human breast milk has not been adequately studied. Animal data show drug presence in milk and potential for kidney effects in nursing offspring. Because of the theoretical risk to the infant's developing kidneys and the absence of human safety data, the FDA label advises against breastfeeding while taking Jardiance. If you are postpartum and wish to breastfeed, discuss timing of Jardiance re-initiation with your clinician after weaning is complete.

Contraception Requirements

Jardiance is not classified as a teratogen requiring mandatory contraception in the same regulatory framework as, for example, isotretinoin or valproate. However, given the second- and third-trimester contraindication, any woman of reproductive age on Jardiance should use effective contraception and have a documented plan for what happens if a pregnancy occurs. Discuss this at every annual diabetes visit.

Side Effects Women Experience More Than Men

Genital Mycotic Infections

This is the most clinically significant sex difference in SGLT2 inhibitor tolerability. Glucosuria, the excretion of glucose in urine that is the drug's mechanism of action, creates a sugar-rich environment in the vaginal and vulvar area. Women on SGLT2 inhibitors experience genital yeast infections at a rate approximately 3 to 5 times higher than men, with rates of 6-8% in women versus 1-2% in men in clinical trials.

What you can do:

• Keep the external genital area dry and clean after urination.
• Wear breathable cotton underwear.
• Report the first episode to your clinician. A single course of fluconazole 150 mg orally typically resolves the infection.
• If you have two or more infections within six months, your clinician may reconsider the drug or prescribe suppressive antifungal therapy.

Women with recurrent vulvovaginal candidiasis at baseline are at higher risk and should be counseled before starting Jardiance.

Urinary Tract Infections

SGLT2 inhibitors have a modest association with urinary tract infections (UTIs) in women, though the EMPA-REG OUTCOME trial did not show a statistically significant increase in serious UTIs. Women already prone to UTIs (postmenopausal women with genitourinary syndrome of menopause, or GSM, are at particular risk because of lower estrogen and vaginal pH changes) should be monitored. Vaginal estrogen to improve genitourinary health may reduce UTI frequency in post-menopausal women on Jardiance; this is an underused combination worth discussing with your clinician.

Euglycemic Diabetic Ketoacidosis

Euglycemic DKA (blood glucose below 250 mg/dL with metabolic acidosis) is a rare but serious adverse event with SGLT2 inhibitors. It occurs more often during surgical fasting, severe illness, or low carbohydrate intake. Women who are pregnant (before they stop the drug), have type 1 diabetes being treated off-label, or are following a very low-carbohydrate diet face elevated risk. The FDA issued a safety communication on this risk in 2015. Jardiance should be held 3-4 days before planned surgery.

Who This Drug Is Right For and Who Should Look at Alternatives

Women Most Likely to Benefit

• Post-menopausal women with type 2 diabetes and established cardiovascular disease or multiple CV risk factors.
• Women with T2D and CKD (eGFR 20-45 mL/min/1.73 m2) who are on maximally tolerated renin-angiotensin system blockade.
• Women with heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, based on the EMPEROR-Reduced trial, which showed a 25% relative risk reduction in the composite of CV death or hospitalization for heart failure.
• Women with T2D who need modest weight loss alongside glucose control and cannot tolerate a GLP-1 receptor agonist.

Women Who Should Avoid Jardiance or Use With Caution

• Women who are pregnant or actively trying to conceive (switch to insulin-based management before conception).
• Women who are breastfeeding.
• Women with recurrent vulvovaginal candidiasis or recurrent UTIs (benefit-risk discussion required).
• Women with eGFR <20 mL/min/1.73 m2 (severely reduced kidney function limits glucose excretion and the drug loses efficacy for T2D, though the kidney-protective benefit may still apply; discuss with nephrology).
• Women with type 1 diabetes (off-label; euglycemic DKA risk is higher and coverage approval is unlikely without specialty documentation).

How to Get Affinity to Approve Jardiance: A Step-by-Step Guide

Insurance denials for Jardiance are common on first submission. Here is what increases approval odds:

Step 1: Make Sure the Diagnosis Code Matches the Indication

Jardiance has FDA approval for:

• Type 2 diabetes mellitus (to improve glycemic control, reduce CV death in adults with T2D and CVD).
• Heart failure (to reduce CV death and hospitalization in adults with HFrEF).
• CKD (to reduce eGFR decline, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression).

If your chart lists only "obesity" or "PCOS" without a concurrent T2D or CKD diagnosis, the authorization will likely be denied.

Step 2: Document Prior Therapy

Your prescriber should document in the authorization letter that metformin was trialed and failed or is contraindicated (for example, due to eGFR below the threshold for metformin safety, or gastrointestinal intolerance). Affinity typically requires at least one step-through agent.

Step 3: Include Lab Values

Attach a recent HbA1c (for T2D indication), eGFR and UACR (for CKD indication), or echocardiogram showing reduced ejection fraction (for HFrEF indication). Authorizations that arrive with lab documentation attached have faster turnaround.

Step 4: Appeal if Denied

A first denial is not final. Affinity is required under New York State Medicaid managed care regulations to provide an internal appeal and, if that fails, an external appeal through an independent review organization. The external appeals process is governed by New York State law and has a track record of overturning denials when clinical documentation is strong. Your clinician can submit a peer-to-peer review call with Affinity's medical director, which often resolves denials faster than the written appeal process.

Step 5: Use the Boehringer Ingelheim Patient Assistance Program While You Wait

While an appeal is pending, the manufacturer's BI Cares Foundation offers free medication for qualifying patients. Eligibility criteria change; ask your clinician's office to submit an application on your behalf. This bridges the gap during the authorization period and avoids a lapse in therapy.

Cost If Affinity Does Not Cover Jardiance

Without insurance coverage, Jardiance costs approximately $620-$700 per month at retail pharmacy. Options to reduce cost:

• Boehringer Ingelheim/Lilly Jardiance Savings Card: Reduces cost for commercially insured patients (not applicable to Medicaid).
• GoodRx or similar discount programs: Can reduce cash price to approximately $500-$550 per month. Still expensive, but relevant if you are in a coverage gap.
• Formulary alternatives: Dapagliflozin (Farxiga) and canagliflozin (Invokana) are related SGLT2 inhibitors with similar cardiovascular and kidney outcomes data. Ask your clinician if one of these is on a preferred Affinity formulary tier and whether the clinical evidence supports substitution for your specific indication.

Dapagliflozin earned FDA approval for HFrEF based on the DAPA-HF trial and for CKD based on the DAPA-CKD trial. Both showed benefits consistent with Jardiance. If dapagliflozin is on a preferred tier, it is a clinically reasonable alternative.

Perimenopause and Post-Menopause: The Cardiovascular Urgency

Women often receive the diagnosis of type 2 diabetes, heart failure, or CKD in their 50s and 60s, overlapping directly with the menopause transition. This timing is not coincidental. Estrogen decline accelerates visceral fat accumulation, raises LDL-C, reduces insulin sensitivity, and increases aortic stiffness. Women in perimenopause who have prediabetes are at elevated risk of progressing to T2D within 5 years.

For post-menopausal women with T2D and any of the following, Jardiance is a first-line add-on agent per ADA 2024: established ASCVD, heart failure, CKD, or high 10-year CV risk. The insurance coverage argument to Affinity is strongest here because the clinical indication is unambiguous and guideline-supported.

Post-menopausal women on Jardiance who also have GSM (genitourinary syndrome of menopause, formerly called vulvovaginal atrophy) face compounded yeast infection risk. Local vaginal estrogen therapy is safe, effective, and does not meaningfully raise systemic estrogen levels. Combining local estrogen with Jardiance to reduce GSM-related yeast and UTI risk is an evidence-informed approach worth discussing with your clinician.

Evidence Gaps Specific to Women

Women were underrepresented in the major SGLT2 inhibitor trials. EMPA-REG OUTCOME enrolled 29% women. EMPEROR-Reduced enrolled 24% women. DAPA-HF enrolled approximately 23% women. This means the cardiovascular and kidney outcome data are largely derived from trials where women were a minority, and sex-stratified subgroup analyses were not powered to detect differential effects.

A 2022 meta-analysis in the Journal of the American College of Cardiology found no statistically significant interaction between sex and SGLT2 inhibitor cardiovascular outcomes, suggesting the benefits likely generalize to women. However, "no significant interaction" is not the same as "equal effect proven in women." Women-specific pharmacokinetic data for empagliflozin are limited; the current dosing (10 mg and 25 mg) was not derived from sex-stratified dose-finding trials.

This evidence gap is a known limitation. You deserve a clinician who acknowledges it plainly and discusses how it affects your individual treatment decision.